Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;22(5):725-734.
doi: 10.3348/kjr.2020.1143. Epub 2021 Feb 2.

Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents

Affiliations

Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents

Yeun Yoon Kim et al. Korean J Radiol. 2021 May.

Abstract

Objective: To intraindividually compare hepatocellular carcinoma (HCC) washout between MRIs using hepatobiliary agent (HBA) and extracellular agent (ECA).

Materials and methods: This study included 114 prospectively enrolled patients with chronic liver disease (mean age, 55 ± 9 years; 94 men) who underwent both HBA-MRI and ECA-MRI before surgical resection for HCC between November 2016 and May 2019. For 114 HCCs, the lesion-to-liver visual signal intensity ratio (SIR) using a 5-point scale (-2 to +2) was evaluated in each phase. Washout was defined as negative visual SIR with temporal reduction of visual SIR from the arterial phase. Illusional washout (IW) was defined as a visual SIR of 0 with an enhancing capsule. The frequency of washout and MRI sensitivity for HCC using LR-5 or its modifications were compared between HBA-MRI and ECA-MRI. Subgroup analysis was performed according to lesion size (< 20 mm or ≥ 20 mm).

Results: The frequency of portal venous phase (PP) washout with HBA-MRI was comparable to that of delayed phase (DP) washout with ECA-MRI (77.2% [88/114] vs. 68.4% [78/114]; p = 0.134). The frequencies were also comparable when IW was allowed (79.8% [91/114] for HBA-MRI vs. 81.6% [93/114] for ECA-MRI; p = 0.845). The sensitivities for HCC of LR-5 (using PP or DP washout) were comparable between HBA-MRI and ECA-MRI (78.1% [89/114] vs. 73.7% [84/114]; p = 0.458). In HCCs < 20 mm, the sensitivity of LR-5 was higher on HBA-MRI than on ECA-MRI (70.8% [34/48] vs. 50.0% [24/48]; p = 0.034). The sensitivity was similar to each other if IW was added to LR-5 (72.9% [35/48] for HBA-MRI vs. 70.8% [34/48] for ECA-MRI; p > 0.999).

Conclusion: Extracellular phase washout for HCC diagnosis was comparable between MRIs with both contrast agents, except for tumors < 20 mm. Adding IW could improve the sensitivity for HCC on ECA-MRI in tumors < 20 mm.

Keywords: Extracellular contrast; Gadoxetic acid; Hepatocellular carcinoma; Magnetic resonance imaging; Washout.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Flowchart of study participants.
ECA = extracellular agent, HBA = hepatobiliary agent, HCC = hepatocellular carcinoma
Fig. 2
Fig. 2. A 46-year-old man with hepatitis B-related liver cirrhosis and hepatocellular carcinoma.
A–C. On the axial T1-weighted 3D turbo field-echo images obtained after gadoxetic acid injection, a 35 mm mass at hepatic segment VII shows (A) non-rim APHE (lesion-to-liver visual SIR, +2), (B) PP washout (visual SIR, −2; temporal reduction in enhancement from AP, −4), and (C) transitional phase washout (visual SIR, −2). D–F. On the axial T1-weighted 3D turbo field-echo images obtained after gadoterate meglumine administration, the mass reveals (D) non-rim APHE (visual SIR, +2), (E) mild hyperintensity (visual SIR, +1) and an enhancing capsule in PP, and (F) delayed phase washout (visual SIR, −2; temporal reduction in enhancement from AP, −4). LR-5 category was assigned on both MRIs by both readers using extracellular phase washout. AP = arterial phase, APHE = arterial phase hyperenhancement, LR-5 = Liver Imaging Reporting and Data System category 5, PP = portal venous phase, SIR = signal intensity ratio, 3D = three-dimensional
Fig. 3
Fig. 3. A 60-year-old man with hepatitis B-related liver cirrhosis and hepatocellular carcinoma.
A–C. On the axial T1-weighted 3D turbo field-echo images obtained after gadoxetic acid injection, a 30-mm mass at hepatic segment VII shows (A) non-rim APHE (visual SIR, +2), (B) PP washout (visual SIR, −1; temporal reduction in enhancement from AP, −3) as well as an enhancing capsule, and (C) transitional phase washout (visual SIR, −2; a temporal reduction from AP, −4). D–F. On the axial T1-weighted 3D turbo field-echo images obtained after gadoterate meglumine administration, the mass reveals (D) non-rim APHE (visual SIR, +2). Isointensities in (E) PP (visual SIR, 0) and (F) delayed phase (visual SIR, 0) and an enhancing capsule indicate IW. LR-5 category was assigned on both MRIs by both readers. However, true washout is present only with hepatobiliary agent-enhanced MRI, while IW is observed with extracellular agent-enhanced MRI. AP = arterial phase, APHE = arterial phase hyperenhancement, IW = illusional washout, LR-5 = Liver Imaging Reporting and Data System category 5, PP = portal venous phase, SIR = signal intensity ratio, 3D = three-dimensional
Fig. 4
Fig. 4. Frequency of washout according to MRI contrast media.
TP indicates washout assessed in TP. IW indicates incorporating IW in the washout definition. DP = delayed phase, ECA = extracellular agent, HBA = hepatobiliary agent, IW = illusional washout, PP = portal venous phase, TP = transitional phase
Fig. 5
Fig. 5. Sensitivity of LR-5 criteria for hepatocellular carcinoma according to washout definition.
As modified LR-5 criteria, TP indicates using washout assessed in TP, and IW indicates allowing IW as washout. DP = delayed phase, ECA = extracellular agent, HBA = hepatobiliary agent, IW = illusional washout, LR-5 = Liver Imaging Reporting and Data System category 5, PP = portal venous phase, TP = transitional phase

Similar articles

Cited by

References

    1. Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25:245–263. - PMC - PubMed
    1. Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, et al. Evidence supporting LI-RADS major features for CT-and MR imaging–based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286:29–48. - PMC - PubMed
    1. Kim YY, Kim MJ, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology. 2019;291:72–80. - PubMed
    1. Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. J Magn Reson Imaging. 2016;43:1337–1345. - PubMed
    1. Stocker D, Becker AS, Barth BK, Skawran S, Kaniewska M, Fischer MA, et al. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions? Eur Radiol. 2020;30:2922–2933. - PubMed